Doxycycline post-exposure prophylaxis among men who have sex with men and transgender women in Belgium: awareness, use and antimicrobial resistance concerns in a cross-sectional online survey
- PMID: 39209541
- PMCID: PMC11877044
- DOI: 10.1136/sextrans-2024-056261
Doxycycline post-exposure prophylaxis among men who have sex with men and transgender women in Belgium: awareness, use and antimicrobial resistance concerns in a cross-sectional online survey
Abstract
Objectives: We aimed to assess the awareness, willingness to use and use of doxycycline post-exposure prophylaxis (doxyPEP) among men who have sex with men (MSM) and transgender women (TGW) in Belgium. Additionally, we aimed to identify factors associated with doxyPEP use and concerns regarding antimicrobial resistance (AMR).
Methods: Cross-sectional online survey among MSM and TGW in Belgium in April 2024. Participants were recruited through sexual networking applications and social media of community-based organisations. Numerical variables were compared with Wilcoxon rank-sum test and categorical variables with χ2 or Fisher's exact tests. Factors associated with doxyPEP use were assessed using logistic regression. Willingness to use doxyPEP and concerns about side effects/AMR were assessed before and after presenting a brief paragraph on the potential effects of doxyPEP on AMR.
Results: 875 individuals initiated the survey. Almost all identified as men (860/875, 98.3%) with a median age of 40 years (IQR 32-48), 40.4% (n=352/875) had heard of doxyPEP and 9.4% (n=82/875) had used it, among whom the majority used it within the previous 6 months (70/81, 86.4%). In multivariable logistic regression, doxyPEP use was associated with reporting ≥1 sexually transmitted infection (STI) in the previous 12 months, engagement in chemsex, HIV status and pre-exposure prophylaxis use, and education level.About 80% of the participants initially reported being willing to use doxyPEP, and about 50% reported being concerned about side effects. After reading about the potential effects of doxyPEP on AMR, willingness to use decreased to 60% and concerns of side effects/AMR increased to around 70%.
Conclusions: Approximately 1 in 10 MSM in Belgium reported using doxyPEP. A recent history of STIs and STI risk factors were positively associated with doxyPEP use. Importantly, concerns about AMR and side effect influenced willingness to use doxyPEP. If doxyPEP is introduced, informing patients about doxyPEP benefits and risks is crucial to enable informed decision-making.
Keywords: Antibiotic Prophylaxis; Chlamydia Infections; Gonorrhea; Post-Exposure Prophylaxis; SYPHILIS.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024.Euro Surveill. 2025 Jul;30(26):2400707. doi: 10.2807/1560-7917.ES.2025.30.26.2400707. Euro Surveill. 2025. PMID: 40613130 Free PMC article.
-
Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends.JAMA Intern Med. 2025 Mar 1;185(3):266-272. doi: 10.1001/jamainternmed.2024.7178. JAMA Intern Med. 2025. PMID: 39761052
-
Early adopters of doxycycline as post-exposure prophylaxis to prevent bacterial sexually transmitted infections in a real-world clinical setting.Sex Transm Infect. 2024 Aug 19;100(6):339-342. doi: 10.1136/sextrans-2024-056152. Sex Transm Infect. 2024. PMID: 38821877
-
Doxycycline post-exposure prophylaxis as prevention of STIs - the golden bullet?Expert Rev Anti Infect Ther. 2025 Jul;23(7):445-457. doi: 10.1080/14787210.2025.2510278. Epub 2025 May 25. Expert Rev Anti Infect Ther. 2025. PMID: 40396488 Review.
-
Doxycycline prophylaxis for the prevention of sexually transmitted infections: A systematic review and meta-analysis of randomized controlled trials.Int J Infect Dis. 2024 Oct;147:107186. doi: 10.1016/j.ijid.2024.107186. Epub 2024 Aug 8. Int J Infect Dis. 2024. PMID: 39122208
Cited by
-
Switching From Dual to Monotherapy for Gonorrhea is Associated With a Halving of Gonococcal Resistance to Azithromycin-A Modelling Study of MSM in Belgium.Open Forum Infect Dis. 2025 Jun 2;12(6):ofaf320. doi: 10.1093/ofid/ofaf320. eCollection 2025 Jun. Open Forum Infect Dis. 2025. PMID: 40568000 Free PMC article.
-
Treponema pallidum infection in asymptomatic persons: A puzzling scenario in the Canary Islands (Spain) (2001-2020).PLoS One. 2025 Jul 8;20(7):e0325073. doi: 10.1371/journal.pone.0325073. eCollection 2025. PLoS One. 2025. PMID: 40627623 Free PMC article.
-
Where we stand on doxyPEP depends on where we sit: a viewpoint.Front Microbiol. 2025 Jun 20;16:1616111. doi: 10.3389/fmicb.2025.1616111. eCollection 2025. Front Microbiol. 2025. PMID: 40620493 Free PMC article.
-
Doxycycline post-exposure prophylaxis in China: current utilized situation among men who have sex with men in a cross-sectional online survey from two cites.BMC Public Health. 2025 Aug 14;25(1):2760. doi: 10.1186/s12889-025-24067-3. BMC Public Health. 2025. PMID: 40814042 Free PMC article.
-
Chemsex and its impact on gay and bisexual men who have sex with men: Findings from an online survey in Belgium.HIV Med. 2025 Feb;26(2):295-301. doi: 10.1111/hiv.13717. Epub 2024 Oct 3. HIV Med. 2025. PMID: 39363611 Free PMC article.
References
-
- Molina J-M, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18:308–17. doi: 10.1016/S1473-3099(17)30725-9. - DOI - PubMed
-
- Molina J-M, Bercot B, Assoumou L, et al. ANRS 174 DOXYVAC: an open-label randomized trial to prevent STIs in MSM on PrEP (CROI abstract 119) Top Antivir Med. 2023;31:49
-
- Molina J-M, Bercot B, Assoumou L, et al. Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design. Lancet Infect Dis. 2024 doi: 10.1016/S1473-3099(24)00236-6. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous